Vignesh Amal Arasu

Vignesh Amal Arasu

Auto-generated profile, based on publicly available information

Vignesh Amal Arasu

Division of Research, Kaiser Permanente Northern California , Pleasanton, CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Radiology
Verified
Journal Article
Closed access
VAVignesh A. Arasu
Vignesh A. Arasu
LHLaurel A. Habel
Laurel A. Habel
NANinah S. Achacoso
Ninah S. Achacoso
DBDiana S. M. Buist
Diana S. M. Buist
JCJason B. Cord
Jason B. Cord
CLCatherine Lee
Catherine Lee
Background Although several clinical breast cancer risk models are used to guide screening and prevention, they have only moderate discrimination. Purpose To compare selected existing mammography artificial intelligence (AI) algorithms and the Breast Cancer Surveillance Consortium (BCSC) risk model for prediction of 5-year risk. Materials and Methods This retrospective case-cohort study included data in women with a negative screening mammographic examination (no visible evidence of cancer) in 2016, who were followed until 2021 at Kaiser Permanente Northern California. Women with prior breast cancer or a highly penetrant gene mutation were excluded. Of the 324 009 eligible women, a random subcohort was selected, regardless of cancer status, to which all additional patients with breast cancer were added. The index screening mammographic examination was used as input for five AI algorithms to generate continuous scores that were compared with the BCSC clinical risk score. Risk estimates for incident breast cancer 0 to 5 years after the initial mammographic examination were calculated using a time-dependent area under the receiver operating characteristic curve (AUC). Results The subcohort included 13 628 patients, of whom 193 had incident cancer. Incident cancers in eligible patients (additional 4391 of 324 009) were also included. For incident cancers at 0 to 5 years, the time-dependent AUC for BCSC was 0.61 (95% CI: 0.60, 0.62). AI algorithms had higher time-dependent AUCs than did BCSC, ranging from 0.63 to 0.67 (Bonferroni-adjusted P < .0016). Time-dependent AUCs for combined BCSC and AI models were slightly higher than AI alone (AI with BCSC time-dependent AUC range, 0.66-0.68; Bonferroni-adjusted P < .0016). Conclusion When using a negative screening examination, AI algorithms performed better than the BCSC risk model for predicting breast cancer risk at 0 to 5 years. Combined AI and BCSC models further improved prediction. © RSNA, 2023 Supplemental material is available for this article.

24 August 2021 in Radiology
Verified
Journal Article
Closed access
NONatsuko Onishi
Natsuko Onishi
WLWen Li
Wen Li
DNDavid C. Newitt
David C. Newitt
RHRoy J. Harnish
Roy J. Harnish
FSFredrik Strand
Fredrik Strand
NHNola Hylton
Nola Hylton
Lack of background parenchymal enhancement suppression at breast MRI during neoadjuvant chemotherapy may indicate inferior treatment response in hormone receptor–positive breast cancer. Background Suppression of background parenchymal enhancement (BPE) is commonly observed after neoadjuvant chemotherapy (NAC) at contrast-enhanced breast MRI. It was hypothesized that nonsuppressed ...

1 December 2016 in Tomography
Verified
Journal Article
Open access
WLWen Li
Wen Li
VAVignesh Arasu
Vignesh Arasu
DNDavid Newitt
David Newitt
EJElla Jones
Ella Jones
LWLisa Wilmes
Lisa Wilmes
NHNola Hylton
Nola Hylton
Tomography is a scientific journal for publication of articles in imaging research

22 July 2020 in Journal of Breast Imaging
Verified
Journal Article
Open access
PDF file
VAVignesh A Arasu
Vignesh A Arasu
PKPaul Kim
Paul Kim
WLWen Li
Wen Li
FSFredrik Strand
Fredrik Strand
CMCody McHargue
Cody McHargue
NHNola M Hylton
Nola M Hylton
Women with advanced HER2− breast cancer have limited treatment options. Breast MRI functional tumor volume (FTV) is used to predict pathologic complete response (pCR) to improve treatment efficacy. In addition to FTV, background parenchymal enhancement (BPE) may predict response and was explored for HER2− patients in the I-SPY-2 TRIAL. Women with HER2− stage II or III breast cancer underwent prospective serial breast MRIs during four neoadjuvant chemotherapy timepoints. BPE was quantitatively calculated using whole-breast manual segmentation. Logistic regression models were systematically explored using pre-specified and optimized predictor selection based on BPE or combined with FTV. A total of 352 MRI examinations in 88 patients (29 with pCR, 59 non-pCR) were evaluated. Women with hormone receptor (HR)+HER2− cancers who achieved pCR demonstrated a significantly greater decrease in BPE from baseline to pre-surgery compared to non-pCR patients (odds ratio 0.64, 95% confidence interval (CI): 0.39–0.92, P = 0.04). The associated BPE area under the curve (AUC) was 0.77 (95% CI: 0.56–0.98), comparable to the range of FTV AUC estimates. Among multi-predictor models, the highest cross-validated AUC of 0.81 (95% CI: 0.73–0.90) was achieved with combined FTV+HR predictors, while adding BPE to FTV+HR models had an estimated AUC of 0.82 (95% CI: 0.74–0.92). Among women with HER2− cancer, BPE alone demonstrated association with pCR in women with HR+HER2− breast cancer, with similar diagnostic performance to FTV. BPE predictors remained significant in multivariate FTV models, but without added discrimination for pCR prediction. This may be due to small sample size limiting ability to create subtype-specific multivariate models.

1 June 2020 in Tomography
Verified
Journal Article
Open access
ANAlex Anh-Tu Nguyen
Alex Anh-Tu Nguyen
VAVignesh A. Arasu
Vignesh A. Arasu
FSFredrik Strand
Fredrik Strand
WLWen Li
Wen Li
NONatsuko Onishi
Natsuko Onishi
NHNola Hylton
Nola Hylton
Breast parenchymal enhancement (BPE) has shown association with breast cancer risk and response to neoadjuvant treatment. However, BPE quantification is challenging, and there is no standardized segmentation method for measurement. We investigated the use of a fully automated breast fibroglandular tissue segmentation method to calculate BPE from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for use as a predictor of pathologic complete response (pCR) following neoadjuvant treatment in the I-SPY 2 TRIAL. In this trial, patients had DCE-MRI at baseline (T0), after 3 weeks of treatment (T1), after 12 weeks of treatment and between drug regimens (T2), and after completion of treatment (T3). A retrospective analysis of 2 cohorts was performed: one with 735 patients and another with a final cohort of 340 patients, meeting a high-quality benchmark for segmentation. We evaluated 3 subvolumes of interest segmented from bilateral T1-weighted axial breast DCE-MRI: full stack (all axial slices), half stack (center 50% of slices), and center 5 slices. The differences between methods were assessed, and a univariate logistic regression model was implemented to determine the predictive performance of each segmentation method. The results showed that the half stack method provided the best compromise between sampling error from too little tissue and inclusion of incorrectly segmented tissues from extreme superior and inferior regions. Our results indicate that BPE calculated using the half stack segmentation approach has potential as an early biomarker for response to treatment in the hormone receptor–negative and human epidermal growth factor receptor 2–positive subtype.

3 February 2018 in Current Radiology Reports
Verified
Journal Article
Closed access
PDF file
VAVignesh A. Arasu
Vignesh A. Arasu
NKNeeta Kannan
Neeta Kannan
PKPriya M. Krishnarao
Priya M. Krishnarao
GKGillian Kuehner
Gillian Kuehner
MKMing C. Kuan
Ming C. Kuan
ALAmie Y. Lee
Amie Y. Lee